Disclosures: Dr. Roeland has disclosed that he is a consultant for Mitobridge Inc., Asahi Kasei Pharmaceuticals, DRG Consulting, Napo Pharmaceuticals, American Imaging Management, Immuneering Corporation, and Prime Oncology. Additionally, he has served on recent advisory boards for Heron Pharmaceuticals, Vector Oncology, and Helsinn Pharmaceuticals. He has also served as a member on data safety monitoring boards for Oragenics, Inc, Galera Pharmaceuticals, and Enzychem Lifesciences Pharmaceutical Company. Dr. Dunne has disclosed that he is a consultant or on an advisory board for Exelixis Inc.
Funding: Dr. Dunne is supported by the University of Rochester CTSA award number KL2TR001999 from the National Center for Advancing Translational Sciences of the National Institutes of Health (RFD).